MedTrace Logo

A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

NCT05212532 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-01-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of EOM613 in this patient population.

Conditions

  • COVID-19 Pneumonia
  • COVID-19 Respiratory Infection
  • COVID-19 Acute Respiratory Distress Syndrome

Interventions

DRUG

EOM613

peptide nucleic acid (PNA)

Sponsors & Collaborators

  • EOM Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Irach Taraporewala, PhD · CEO and Director, EOM Pharma

  • Frank L Douglas, PhD, MD · Scientific Advisor & Chair of Scientific Advisory Board, EOM Pharma

  • Florentino Cardoso Filho, MD, PhD · Physician, Casa de Saude Hospital, Campinas, SP

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2022-02-28
Completion
2022-03-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212532 on ClinicalTrials.gov